THE SUCCESSFUL use of BCG (bacillus Calmette-Guerin) in the treatment of animals and humans bearing tumours has been reported (Old, Clarke and Benacerraf, 1959; Mathe et al., 1969; Bast et al., 1974) . MER is a methanol extraction residue of BCG; it is not viable and has a broad activity as a stimulant of immunological reactivity and of resistance to microbial pathogens and neoplastic cells (Weiss and Dubos, 1955; Weiss, Bonhag and Leslie, 1966; Weiss, 1972; Robinson et al., 1972) .
Previously, we have reported in tumour bearing mice that radiotherapy and chemotherapy combined with MER treatment tend to be more effective in reducing tumour volume and prolonging the survival of the animals than radio-or chemotherapy alone (Yron et al., 1973) . In the present study of inoperable cancer patients, we have evaluated the tolerance to MER, its effect on the disease and the skin reactivity to recall antigens.
MATERIALS AND METHODS
Patients.-Twenty-seven patients with histologically confirmed malignant neoplasia were included in this study; Table I shows the diagnoses. Twenty-one of the patients suffered from inoperable advanced epithelial cancer and 6 with malignant melanoma; all melanoma patients underwent resection of the primary and metastatic regional lymph nodes and had no evidence of disease. All the patients except one had a life expectancy of more than 3 months. The patients were examined at least every 2 weeks and received conventional treatment, radio-and/or chemotherapy according to standard protocols used in our department. The informed consent of the patients was obtained before admission to the study.
Test antigens. Eighteen patients were skin tested by intradermal injection of 0-1 ml of 3 recall antigen preparations. 
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After 3 or more courses of MER, the reaction was found to be strong in 10 patients, medium in 7 and weak in 3 (a change from weak to medium or to strong from medium). MER induced in most patients a local inflammatory reaction which sometimes progressed to necrosis, ulceration and squama formation.
The injection sites usually became slightly painful and rarely secreted variable amounts of caseous material. After repeated injections of MER, a typical flare up phenomenon of the previous sites of injection was observed. All lesions resolved in a period of 3-6 weeks.
In 3 of the 27 patients, regional lymph nodes became palpable and tender with repeated injections and regressed spontaneously after 6 weeks. Four patients had fever up to 39°C with malaise that lasted 24-72 h after injection. One patient with lung cancer had a general eruption, appearing 10 days after the second course of MER with a rash resembling the reaction in the MER injection sites. This patient was known to suffer from rheumatic fever and other allergic reactions.
Liver function tests including albumin, globulin, alkaline phosphatase, cephalin, thymol, transaminase, were normal in all patients. 18 patients. Five of these 9 patients received treatment every other week and 4 once a month (Table IV) . Both groups of patients received 3-6 courses of MER, except one patient in Schedule B who received 10 courses of MER.
Of the 27 patients, 5 patients died from their tumour during the course of the study; 4 of these received 1-2 courses of MER and one received 4 courses. The other 22 patients are still living more than 6 months after diagnosis. All these patients except one showed no progression in their disease. The latter is a patient with malignant melanoma who, during a local recurrence, received his first treatment of MER. Though he received a further course of immunotherapy, his disease progressed but all his skin tests remained positive.
It is worth noting that the 4 patients (Table IV) whose skin reactivity deteriorated in spite of MER treatment are still without evidence of progression in their disease. (Mathe et al., 1969; Morton et al., 1970; Gutterman et al., 1974) , but serious side-effects to this treatment have also been described Hunt, Silverstein and Sparks, 1973) . In contrast, the MER fraction of BCG has the advantage over the living organism of being a non-viable material. In mice, it has been proved to have considerable therapeutic efficacy and no side-effects (Yron et al., 1973) .
In the present work, we have shown that MER can be given every other week or once a month with no serious complications. Patients who were anergic to a battery of skin tests had a low or no local reaction to the MER injection. In 9 patients the skin reactivity became stronger during treatment. This occurred more often in patients treated every other week (5 of 6 patients) than in patients treated with MER once a month (4 of 12). Because of the local reactions, MER immunotherapy should not be given more frequently.
The danger that overstimulation of the immune response would enhaince tumour growth (Baldwin and Pimm, 1973a, b; Piessens et al., 1970 Piessens et al., , 1971 should also be taken into consideration when the number and schedules of treatment are decided.
It is apparent that MER has no serious deleterious side-effects in man and is well tolerated by the patients. As to the one case where a skin eruption developed, it must be noted that similar phenomena have been observed with BCG treatment (Hersh, personal communication 
